CD19 and neoplasm: Cytotoxicity assays demonstrated that overexpressing CD2 increased the ability of different CAR-T cells, which employ either 4-1BB or CD28 as the costimulatory domain, to eliminate CD19-low-expressing tumor cells (Fig. 6A).